Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications (Sugammadex)
Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery And Postoperative Complications In Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial
Sponsor: Merck Canada Inc.
This PHASE4 trial investigates Obstructive Sleep Apnea and is currently completed. Merck Canada Inc. leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Nov 2021 — Nov 2022 [monthly]
Recruiting PHASE4
▶ Show 6 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE4
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE4
-
Apr 2020 — Dec 2020 [monthly]
Recruiting PHASE4
-
Feb 2019 — Apr 2020 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Dec 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE4
-
Oct 2018 — Dec 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Canada Inc.
- University Health Network, Toronto
For direct contact, visit the study record on ClinicalTrials.gov .